Long term follow-up of international randomised phase 3 study of rituximab versus a watch and wait approach for patients with asymptomatic, low tumour burden follicular lymphoma shows rituximab is highly effective at delaying time to new treatment without detrimental impact following next line of therapy

2024-11-0920220006-497110.1182/blood-2022-156790http://dx.doi.org/10.1182/blood-2022-156790https://hdl.handle.net/20.500.14288/9203N/AHematologyLong term follow-up of international randomised phase 3 study of rituximab versus a watch and wait approach for patients with asymptomatic, low tumour burden follicular lymphoma shows rituximab is highly effective at delaying time to new treatment without detrimental impact following next line of therapyMeeting Abstract1528-0020893223201193Q111959